Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367163516> ?p ?o ?g. }
- W4367163516 endingPage "767" @default.
- W4367163516 startingPage "758" @default.
- W4367163516 abstract "A paucity of effective treatment for biliary tract carcinoma (BTC) has necessitated the investigation into new therapies. As combinations of targeted therapy with immunotherapy are well-established in hepatocellular carcinoma, the GEMOX chemotherapy (gemcitabine and oxaliplatin) is the standard treatment for BTC. This study aimed to evaluate the efficacy and safety of immunotherapy in combination with targeted agent and chemotherapy in advanced BTC.Patients who were pathologically identified advanced BTC and had received gemcitabine-based chemotherapy alone or in combination with anlotinib, and/or anti-programmed cell death protein-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors such as camrelizumab as first-line treatment were retrospectively screened from The First Affiliated Hospital of Guangxi Medical University from February 2018 to August 2021. The outcomes included objective response rate (ORR), median overall survival (OS), and median progressive-free survival (PFS). Adverse events (AEs) were assessed according to the NCI-CTCAE v. 4.03. Patients were followed up weekly.A total of 35 patients were enrolled in this study: 11 patients treated with PD-1/PD-L1 inhibitor plus anlotinib and gemcitabine (arm A), 12 patients with the GEMOX combined with PD-1/PD-L1 inhibitor (arm B), and 12 patients with GEMOX (arm C). With a median follow-up time of 31.9 months (range, 23.8-39.7 months), the median OS was 16.8 months [95% confidence interval (CI): 7.0-not reached], 11.8 months (95% CI: 7.2-31.7 months), and 11.6 months (95% CI: 7.3-18.0 months) in arms A, B, and C, respectively (P=0.298). The median PFS was 16.8 months (95% CI: 7.0-NR), 6.0 months (95% CI: 5.1-8.7 months), and 6.3 months (95% CI: 4.6-7.0 months) in arms A, B, and C, respectively. The ORR were 63.6% in arm A, 33.3% in arm B, and 25.0% in arm C. AEs of all grades occurred in 33 (94.3%) patients. Grade 3-4 AEs in all patients included neutrophil count decrease (14.3%), aspartate aminotransferase increase (8.6%), alanine aminotransferase increase (8.6%), fatigue (5.7%), and blood bilirubin increase (5.7%).Anti-PD-1/PD-L1 immunotherapy in combination with anlotinib and gemcitabine showed promising efficacy and an acceptable safety profile for the BTC patients included in this study." @default.
- W4367163516 created "2023-04-28" @default.
- W4367163516 creator A5006160595 @default.
- W4367163516 creator A5015846827 @default.
- W4367163516 creator A5018705727 @default.
- W4367163516 creator A5034555673 @default.
- W4367163516 creator A5042275051 @default.
- W4367163516 creator A5048552499 @default.
- W4367163516 creator A5054993402 @default.
- W4367163516 creator A5062896936 @default.
- W4367163516 creator A5063128754 @default.
- W4367163516 creator A5064915604 @default.
- W4367163516 creator A5075571728 @default.
- W4367163516 creator A5090283553 @default.
- W4367163516 date "2023-04-01" @default.
- W4367163516 modified "2023-10-18" @default.
- W4367163516 title "A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma" @default.
- W4367163516 cites W2028640470 @default.
- W4367163516 cites W2071862424 @default.
- W4367163516 cites W2115261608 @default.
- W4367163516 cites W2937317161 @default.
- W4367163516 cites W2949307886 @default.
- W4367163516 cites W2984293721 @default.
- W4367163516 cites W2995326499 @default.
- W4367163516 cites W3022210979 @default.
- W4367163516 cites W3025022288 @default.
- W4367163516 cites W3039360174 @default.
- W4367163516 cites W3044745358 @default.
- W4367163516 cites W3105802462 @default.
- W4367163516 cites W3124058635 @default.
- W4367163516 cites W3144916167 @default.
- W4367163516 cites W3156802528 @default.
- W4367163516 cites W3166753505 @default.
- W4367163516 cites W3176513769 @default.
- W4367163516 cites W3184493479 @default.
- W4367163516 cites W3216831771 @default.
- W4367163516 cites W4220891579 @default.
- W4367163516 cites W4327686636 @default.
- W4367163516 doi "https://doi.org/10.21037/jgo-23-218" @default.
- W4367163516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37201053" @default.
- W4367163516 hasPublicationYear "2023" @default.
- W4367163516 type Work @default.
- W4367163516 citedByCount "1" @default.
- W4367163516 countsByYear W43671635162023 @default.
- W4367163516 crossrefType "journal-article" @default.
- W4367163516 hasAuthorship W4367163516A5006160595 @default.
- W4367163516 hasAuthorship W4367163516A5015846827 @default.
- W4367163516 hasAuthorship W4367163516A5018705727 @default.
- W4367163516 hasAuthorship W4367163516A5034555673 @default.
- W4367163516 hasAuthorship W4367163516A5042275051 @default.
- W4367163516 hasAuthorship W4367163516A5048552499 @default.
- W4367163516 hasAuthorship W4367163516A5054993402 @default.
- W4367163516 hasAuthorship W4367163516A5062896936 @default.
- W4367163516 hasAuthorship W4367163516A5063128754 @default.
- W4367163516 hasAuthorship W4367163516A5064915604 @default.
- W4367163516 hasAuthorship W4367163516A5075571728 @default.
- W4367163516 hasAuthorship W4367163516A5090283553 @default.
- W4367163516 hasBestOaLocation W43671635161 @default.
- W4367163516 hasConcept C121608353 @default.
- W4367163516 hasConcept C126322002 @default.
- W4367163516 hasConcept C141071460 @default.
- W4367163516 hasConcept C143998085 @default.
- W4367163516 hasConcept C197934379 @default.
- W4367163516 hasConcept C2776694085 @default.
- W4367163516 hasConcept C2777701055 @default.
- W4367163516 hasConcept C2780258809 @default.
- W4367163516 hasConcept C2780962732 @default.
- W4367163516 hasConcept C2781230642 @default.
- W4367163516 hasConcept C526805850 @default.
- W4367163516 hasConcept C71924100 @default.
- W4367163516 hasConcept C90924648 @default.
- W4367163516 hasConceptScore W4367163516C121608353 @default.
- W4367163516 hasConceptScore W4367163516C126322002 @default.
- W4367163516 hasConceptScore W4367163516C141071460 @default.
- W4367163516 hasConceptScore W4367163516C143998085 @default.
- W4367163516 hasConceptScore W4367163516C197934379 @default.
- W4367163516 hasConceptScore W4367163516C2776694085 @default.
- W4367163516 hasConceptScore W4367163516C2777701055 @default.
- W4367163516 hasConceptScore W4367163516C2780258809 @default.
- W4367163516 hasConceptScore W4367163516C2780962732 @default.
- W4367163516 hasConceptScore W4367163516C2781230642 @default.
- W4367163516 hasConceptScore W4367163516C526805850 @default.
- W4367163516 hasConceptScore W4367163516C71924100 @default.
- W4367163516 hasConceptScore W4367163516C90924648 @default.
- W4367163516 hasIssue "2" @default.
- W4367163516 hasLocation W43671635161 @default.
- W4367163516 hasLocation W43671635162 @default.
- W4367163516 hasLocation W43671635163 @default.
- W4367163516 hasOpenAccess W4367163516 @default.
- W4367163516 hasPrimaryLocation W43671635161 @default.
- W4367163516 hasRelatedWork W1991358584 @default.
- W4367163516 hasRelatedWork W2007621813 @default.
- W4367163516 hasRelatedWork W2054312082 @default.
- W4367163516 hasRelatedWork W2349340765 @default.
- W4367163516 hasRelatedWork W2383559318 @default.
- W4367163516 hasRelatedWork W2410090482 @default.
- W4367163516 hasRelatedWork W2811271347 @default.
- W4367163516 hasRelatedWork W2910998150 @default.